| Patient | Ada Lovelace |
|---|---|
| Date of birth | 1990-12-10 |
| Identifiers | MRN HR-NI031-SYN; SSN (made up) 000-31-6729 |
| Document date | 2026-06-16 |
| Author | Beatrix Lindgren-Osei, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Friable exophytic cervical mass with five months of abnormal bleeding and constant pelvic pain in a 35-year-old woman, biopsied today, with iron deficiency anemia. Please confirm the diagnosis, stage the disease, advise on treatment intent and options, and help with control of bleeding and pain. [S]
Urgency: Within two weeks; pathology expected within a week. [S]
Questions for the consultant:
Mrs. Lovelace, a 35-year-old mathematician, is seen at the request of Dr. Whitley-Adeyemi for a cervical mass found two weeks ago after five months of abnormal bleeding and pelvic pain. The bleeding is lighter since the first iron infusion but continues. Her pain averages 6 of 10 on oral morphine solution 5 mg about six times a day, without drowsiness; she stopped the opium tincture she had taken for two years. She has no cough, hemoptysis, bone pain, leg swelling, or urinary or bowel symptoms beyond opioid-related constipation. She has never had cervical screening. She does not wish to preserve fertility. She asked to be told the findings directly. [S]
Historical basis. These claims are historical evidence, not findings from a modern examination.
3 later historical claims are omitted because they describe events after the index age. See the teaching note.
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Opium tincture (100 mg/mL opium, equivalent to 10 mg/mL morphine), 0.5 mL by mouth four to six times a day as needed for pain | 0.5 mL four to six times a day as needed | Oral route | 2024-06-03 to 2026-06-02 | completed | S |
| Morphine sulfate oral solution 2 mg/mL, 5 mg (2.5 mL by oral syringe) every 4 hours as needed for pain | 5 mg every 4 hours as needed | Oral route | 2026-06-02 | active | S |
| Morphine sulfate extended-release 15 mg tablet, one tablet by mouth every 12 hours; swallow whole | every 12 hours | Oral route | 2026-06-16 to 2026-10-20 | completed | S |
| Naloxone 4 mg nasal spray, one spray in a nostril for suspected opioid overdose; call 911 | one spray as needed for suspected overdose; repeat after 2 to 3 minutes if needed | Nasal route | 2026-06-02 | active | S |
| Senna 8.6 mg tablet, two tablets by mouth at night | two tablets at night | Oral route | 2026-06-02 | active | S |
| Polyethylene glycol 3350, 17 g in water by mouth once or twice a day | once daily, up to twice daily | Oral route | 2026-06-02 | active | S |
| Acetaminophen 500 mg tablet, two tablets by mouth three times a day | 1 g three times a day | Oral route | 2026-06-02 | active | S |
| Ferric carboxymaltose 750 mg intravenous infusion, two doses at the first two visits | 750 mg on two occasions two weeks apart | Intravenous route | 2026-06-02 to 2026-06-17 | completed | S |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Bleeding between periods and after intercourse, with heavier periods, a watery blood-stained discharge and a constant pelvic ache, for about five months; average pain 7 of 10 despite her opium tincture; a friable cervical mass found on examination and biopsied; cause not yet established at intake | resolved | confirmed | N93.8 | S — Synthetic presenting problem anchored to her documented final illness; superseded by the diagnosis at the second visit. |
| Iron deficiency anemia from chronic blood loss: hemoglobin 8.4 g/dL, mean cell volume 74 fL, ferritin 5 ng/mL, with tiredness and breathlessness on stairs | active | confirmed | D50.0 | S — Synthetic modern finding anchored to her documented final illness. |
| Adenocarcinoma of the endocervix, usual (HPV-associated) type, HPV 18 positive, FIGO 2018 stage IVB: a 5.2 cm tumor with left parametrial invasion, metastases to left pelvic and para-aortic lymph nodes, and bilateral lung metastases on MRI and PET-CT; PD-L1 combined positive score 5, mismatch repair proficient, HER2 1+; treated with palliative pelvic radiation for bleeding and carboplatin, paclitaxel and pembrolizumab, with specialist palliative care from diagnosis | active | confirmed | C53.0 | S — Synthetic modern diagnosis made at the second visit, anchored to her documented uterine cancer; the cervical site is a synthetic choice. |
| Cancer-related pelvic pain, nociceptive and visceral, from the cervical tumor and its left parametrial extension | active | confirmed | G89.3 | S — Synthetic modern diagnosis made at the second visit. |
| Long-term prescribed opioid therapy: opium tincture for recurrent pelvic and abdominal pain for about two years, measured at times with a household spoon, converted at intake to measured oral morphine; no opioid use disorder on a DSM-5 assessment; naloxone supplied | active | confirmed | Z79.891 | S — Synthetic modern history anchored to her documented laudanum and opium; not a claim about her real dosing. |
Vital signs recorded on 2026-06-16; see the referring visit's Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Pale, alert, not sedated; blood pressure 106/66, pulse 92; ECOG performance status 1 |
| Lymph nodes | No supraclavicular or inguinal lymph node enlargement |
| Abdomen | Soft; mild suprapubic tenderness; no masses |
| Pelvis | Exophytic friable cervical tumor about 5 cm with light bleeding; left parametrial thickening not reaching the sidewall; vagina free; rectovaginal septum free |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-06-16 | Hemoglobin [Mass/volume] in Blood | 9 | g/dL | 12-15.5 g/dL | Low | S |
| 2026-06-16 | Creatinine [Mass/volume] in Serum or Plasma | 0.66 | mg/dL | 0.57-1 mg/dL | Normal | S |
| 2026-06-16 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 17 | U/L | 7-35 U/L | Normal | S |
| 2026-06-16 | Thyrotropin [Units/volume] in Serum or Plasma | 1.9 | m[IU]/L | 0.45-4.5 mIU/L | Normal | S |
| 2026-06-16 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1.2 | ng/dL | 0.8-1.8 ng/dL | Normal | S |
| 2026-06-16 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 117 | mL/min/{1.73_m2} | 60 or more | Normal | S |
| 2026-06-16 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 6 | {score} | S |
Data reviewed: Cervical biopsy: invasive adenocarcinoma, usual (HPV-associated) type, p16 diffusely positive, HPV 18 detected; PD-L1 combined positive score 5; mismatch repair proteins retained; HER2 immunohistochemistry 1+. Pelvic MRI a week ago: 5.2 cm endocervical tumor with left parametrial invasion, not reaching the sidewall, no hydronephrosis, an enlarged left external iliac node. FDG PET-CT five days ago: avid tumor, avid left pelvic and para-aortic nodes, six avid nodules in both lungs up to 1.4 cm, no bone or liver lesions. Hemoglobin 9.0 g/dL today, from 8.4; creatinine 0.66 mg/dL; ALT 17 U/L; TSH 1.9 mIU/L; HIV, hepatitis B and hepatitis C tests negative. [S]